Search

Your search keyword '"Mark Hennon"' showing total 5 results
Start Over Author "Mark Hennon" Journal journal of the national comprehensive cancer network
5 results on '"Mark Hennon"'

1. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Author

Jessica Bauman, Alda Tam, Christine M. Lovly, Scott N. Gettinger, Daniel Morgensztern, Aditi P. Singh, Steven E. Schild, Miranda Hughes, Lucian R. Chirieac, Debora S. Bruno, Erminia Massarelli, Aparna Hegde, Renato Martins, Jane Yanagawa, Thomas Ng, Ankit Bharat, Billy W. Loo, Douglas E. Wood, Matthew A. Gubens, Theresa A. Shapiro, Mark Hennon, Gregory J. Riely, Gregory A. Otterson, James P. Stevenson, Rudy P. Lackner, Kristina M. Gregory, Joe Y. Chang, Dara L. Aisner, Jules Lin, Jonathan E. Dowell, Sandip P. Patel, Stephen C. Yang, Thomas A. D'Amico, Wallace Akerley, Thomas J. Dilling, David S. Ettinger, Michael Lanuti, and Ticiana A. Leal

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.disease, respiratory tract diseases, Clinical Practice, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, Non small cell, business, Lung cancer
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

Published
2021
Full Text
View/download PDF

2. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Author

Gregory J. Riely, Thomas A. D'Amico, Ticiana A. Leal, Leora Horn, Thomas J. Dilling, Renato Martins, Kurt Tauer, Debora S. Bruno, Charu Aggarwal, Steven E. Schild, Joe Y. Chang, Rudy P. Lackner, Matthew A. Gubens, Mark Hennon, Michael C. Dobelbower, Karen L. Reckamp, Miranda Hughes, David S. Ettinger, Michael Lanuti, James P. Stevenson, Theresa A. Shapiro, Scott J. Swanson, Ramaswamy Govindan, Scott N. Gettinger, Gregory A. Otterson, Jules Lin, Billy W. Loo, Stephen C. Yang, Dara L. Aisner, Sandip Pravin Patel, Ankit Bharat, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Kristina M. Gregory, and Lucian R. Chirieac

Subjects
medicine.medical_specialty, Lung Neoplasms, business.industry, Psychological intervention, MEDLINE, Antineoplastic Agents, medicine.disease, Systemic therapy, respiratory tract diseases, Oncology, Carcinoma, Non-Small-Cell Lung, Practice Guidelines as Topic, medicine, Humans, Immunotherapy, Non small cell, Lung cancer, business, Intensive care medicine
Abstract

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”

Published
2019
Full Text
View/download PDF

3. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Author

Matthew A. Gubens, Theresa A. Shapiro, Douglas E. Wood, Gregory J. Riely, Lucian R. Chirieac, Karen L. Reckamp, Leora Horn, Renato G. Martins, Gregory A. Otterson, Michael C. Dobelbower, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Dara L. Aisner, Sandip Pravin Patel, Stephen C. Yang, Michael Lanuti, Kristina M. Gregory, James P. Stevenson, Scott J. Swanson, Ticiana A. Leal, Billy W. Loo, Jules Lin, Mark Hennon, Rogerio Lilenbaum, Miranda Hughes, Ramaswamy Govindan, Joe Y. Chang, Thomas A. D'Amico, Thomas J. Dilling, Steven E. Schild, Wallace Akerley, and Jessica Bauman

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Medical Oncology, Neoplasm genetics, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Molecular Targeted Therapy, Progression-free survival, Lung cancer, Societies, Medical, Randomized Controlled Trials as Topic, business.industry, Disease progression, medicine.disease, Progression-Free Survival, United States, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Non small cell, business
Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

Published
2018
Full Text
View/download PDF

4. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Lucian R. Chirieac, Jessica Bauman, Thomas A. D'Amico, Thomas J. Dilling, Leah J. Leisch, Steven E. Schild, Ticiana A. Leal, Douglas E. Wood, Scott J. Swanson, Robert C. Doebele, Wallace Akerley, Renato Martins, James P. Stevenson, Mark Hennon, Leora Horn, Rogerio Lilenbaum, Malcolm M. DeCamp, Gregory A. Otterson, Dara L. Aisner, Kristina M. Gregory, Miranda Hughes, Karen L. Reckamp, Ramaswamy Govindan, Theresa A. Shapiro, Billy W. Loo, Matthew A. Gubens, Jules Lin, Gregory J. Riely, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Michael Lanuti, Ritsuko Komaki, Michael C. Dobelbower, and Stephen C. Yang

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Disease, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Combined Modality Therapy, Osimertinib, Molecular Targeted Therapy, Neoplasm Metastasis, Lung cancer, Clinical Trials as Topic, Ceritinib, business.industry, Disease Management, Immunotherapy, Prognosis, medicine.disease, respiratory tract diseases, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Biomarkers, medicine.drug
Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Published
2017
Full Text
View/download PDF

5. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Author

Lyudmila Bazhenova, Thierry Jahan, Jyoti D. Patel, Scott J. Swanson, Ramaswamy Govindan, Jules Lin, Gregory A. Otterson, Kurt Tauer, Karen L. Reckamp, M. Chris Dobelbower, Thomas A. D'Amico, Lucian R. Chirieac, Wallace Akerley, Thomas J. Dilling, D.R. Camidge, Katherine M.W. Pisters, Stephen C. Yang, Michael Lanuti, James P. Stevenson, Neelesh Sharma, Mark Hennon, Rogerio Lilenbaum, Renato G. Martins, Miranda Hughes, Gregory J. Riely, David S. Ettinger, Leora Horn, Rudy P. Lackner, Steven E. Schild, Billy W. Loo, Richard T. Cheney, Theresa A. Shapiro, Kristina M. Gregory, Douglas E. Wood, Ritsuko Komaki, and Hossein Borghaei

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Pembrolizumab, medicine.disease, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Non small cell, Nivolumab, Lung cancer, Adverse effect, business, Survival rate, medicine.drug
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results